Market Research Logo

Prescription Drugs Market Research Reports & Industry Analysis

In April 2011, the Food and Drug Administration (FDA) announced a new program focused on curbing the abuse and reducing associated risks of prescription opioid painkillers. The Risk Evaluation and Mitigation Strategy (REMS) program focuses primarily on educating doctors about proper pain management, patient selection and improving patient awareness about how to use these drugs safely.

According to the White House, prescription drug abuse has become an epidemic, estimating that in 2007 alone, over 33 million Americans age 12 and older misused opioid painkillers. That same year, drug overdose in the U.S. was one of the leading causes of unintentional injury death, second only to motor vehicle accidents.

One important target of the campaign is the safe disposal of medications. In many cases, doctors have been found to prescribe larger doses of opioids than patients actually use. Many of these pills find their way onto the black market. Additionally, more than half of all non-prescribed painkiller users get their drugs from someone they know. As part of the plan, FDA wants opioid manufacturers to provide prescribing physicians with educational materials, including a medication guide that uses consumer friendly language to explain safe use and disposal.

The drugs targeted by the REMS plan include brand name products known under the generic names hydromorphone, oxycodone, morphine, oxymorphone, methadone, transdermal fentanyl, and transdermal buprenorphine.

...Show More ...Show Less


Filter your search

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Prescription Drugs Industry Research & Market Reports

  • Global and Chinese Amoxicillin Industry, 2017 Market Research Report

    ...report provides key statistics on the market status of the Amoxicillin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview ... Read More

  • Argentina Pharmaceuticals and Healthcare Report Q4 2017

    ...demand for chronic disease treatment. Moreover, ongoing improvementsto the regulatory environment pose upside risks to patented medicine sales. Headline Expenditure Projections Pharmaceuticals: ARS80.27bn (USD5.43bn) in 2016 to ARS97.10bn (USD5.88bn) in 2017; +21.0% inlocal currency terms ... Read More

  • Brazil Pharmaceuticals and Healthcare Report Q4 2017

    ...challenging market due to price and market access controls. Headline Expenditure Projections Pharmaceuticals: BRL73.65bn (USD19.87bn) in 2016 to BRL77.64bn (USD23.89bn) in 2017; +5.4%in local currency terms and +20.2% in US dollar terms. Local currency forecast ... Read More

  • Australia Pharmaceuticals and Healthcare Report Q4 2017

    ...create revenue challenges for multinationalpharmaceutical firms. While innovative pharmaceutical treatments will stand to gain from the introductionof a Priority Review and a Provisional Approval process in the country, the net benefit will remainconstrained by the ... Read More

  • El Salvador Pharmaceuticals and Healthcare Report Q4 2017

    ...of Health's efforts to solicit outside assistance to bolster healthcareprovision in all quarters of the country. Despite improvements in the regulatory environment since TheMedicines Law of El Salvador was approved in 2012, steady multinational FDI ... Read More

  • Latin America Pharmaceuticals and Healthcare Report Q4 2017

    ...regulatory advancements will maintaindrugmaker interest in the long term. Headline Expenditure Projections Pharmaceuticals: USD57.5bn in 2016 to USD63.3bn in 2017; 10.0% in US dollar terms. Healthcare: USD363.6bn in 2016 to USD404.8bn in 2017; 11.3% in ... Read More

  • Sub-Saharan Africa Pharmaceuticals and Healthcare Report Q4 2017

    ...the region, where the rewards are brighter forinnovative drugmakers' portfolios and have longer-term potential. Headline Expenditure Projections Pharmaceuticals: USD12.0bn in 2016 to USD12.3bn in 2017; 3.1% in US dollar terms. Healthcare: USD79.1bn in 2016 to ... Read More

  • Singapore Pharmaceuticals and Healthcare Report Q4 2017

    ...involvement of the government,Singapore's pharmaceutical and healthcare sector is set to grow and evolve, making the country's healthcaresector increasingly attractive to investors, thereby boosting both the country's economy and the population'soverall well-being. Pricing will also ... Read More

  • Middle East And North Africa Pharmaceuticals and Healthcare Report Q4 2017

    ...diversifiedtherapeutic development from firms in the region. Crucially, a country-specific approach is integral forpharmaceutical companies as they must adapt to the evolving pricing landscape, differing levels of patentprotection and the level of competition within each ... Read More

  • Zambia Pharmaceuticals and Healthcare Report Q4 2017

    ...force unemployed, geographical and financial access to medicines forthe majority of the population is largely restricted. Headline Expenditure Forecast Pharmaceuticals: ZMW1.80bn (USD174mn) in 2016 to ZMW1.93bn (USD204mn) in 2017; +7.4% inlocal currency terms and 17.2% ... Read More

  • Bangladesh Pharmaceuticals and Healthcare Report Q4 2017

    ...Growing public healthcare spending and the government's efforts to improve the regulatory environmentwill be positive for the sector's development, although the large share of out-of-pocket spending as apercentage of health expenditure, as well as low ... Read More

  • Costa Rica Pharmaceuticals and Healthcare Report Q4 2017

    ...medical tourism destination and expandinghealthcare infrastructure that will need to cater to its gradually ageing population. However, the smallmarket size will continue to hamper its growth potential as well as its relative attractiveness. Headline Expenditure ... Read More

  • Pakistan Pharmaceuticals and Healthcare Report Q4 2017

    ...The unmet need for non-communicable disease treatments among low-income patients will createopportunities to provide affordable medicines. Headline Expenditure Projections Pharmaceuticals: PKR275.8bn (USD2.6bn) in 2016 to PRK301.2bn (USD2.9bn) 2017; +9.2% in localcurrency terms and +9.3% in ... Read More

  • Tunisia Pharmaceuticals and Healthcare Report Q4 2017

    ...a notable impact on developments within the pharmaceutical sector and wider economy;however, the actual benefits will take time to materialise. Crucially, higher growth opportunities willpresent themselves within the generic medicines sector, while the high industry-associated ... Read More

  • Slovakia Pharmaceuticals and Healthcare Report Q4 2017

    ...this willpose fewer risks to drugmakers, Slovakia's market has less potential for growth than some of its similarlydevelopedregional neighbours, notably Poland. Headline Expenditure Projections Pharmaceuticals: EUR1.72bn (USD1.90bn) in 2016 to EUR1.80bn (USD1.98bn) in 2017; +4.7% ... Read More

  • Nicaragua Pharmaceuticals and Healthcare Report Q4 2017

    ...of the overallmarket is among the smallest in Central America and is limited by a largely low-income population with astrong preference for traditional medicines. Furthermore, weak drug regulatory framework and poorhealthcare infrastructure will dampen multinational ... Read More

  • Philippines Pharmaceuticals and Healthcare Report Q4 2017

    ...the specific target of the 2017 budget is to expand healthcare access to low-income Filipinos. Moreover, the constraints on affordability and the demand for low-cost pharmaceuticals will spur greaterinvestment from drugmakers with strong generic drug ... Read More

  • Ethiopia Pharmaceuticals and Healthcare Report Q4 2017

    ...Ethiopia remains a long way from achieving sustainable medicine production. Greaterinterest from foreign investors and further government support will boost the capacity of Ethiopia'spharmaceutical landscape over the long term; however, opportunities for patented firms will ... Read More

  • Slovenia Pharmaceuticals and Healthcare Report Q4 2017

    ...of treatment quality and effectiveness. Inaddition, the healthcare system is experiencing rising debts to employees, which has been blamed oninefficient spending. Slovakia's pharmaceutical market, however, will remain one of the most attractive inCEE over the ... Read More

  • Manufacture of pharmaceutical products (GERMANY) - Industry Report

    ...AG & Co. KG, GlaxoSmithKline Beteiligungs GmbH and Overlack AG. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Manufacture of pharmaceutical products (GERMANY) analysis ... Read More

  • Pharmaceutical Wholesalers (NORDIC) - Industry Report

    ...OYJ. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Wholesalers (NORDIC) analysis is ideal for anyone wanting to: • See the market leaders ... Read More

  • Wholesale of pharmaceutical goods (GERMANY) - Industry Report

    ...Lilly Deutschland GmbH and CRANACH-PHARMA GmbH. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Wholesale of pharmaceutical goods (GERMANY) analysis is ideal for anyone ... Read More

  • Pharmaceutical Manufacturers (SWEDEN) - Industry Report

    ...FUJIREBIO DIAGNOSTICS AB. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Manufacturers (SWEDEN) analysis is ideal for anyone wanting to: • See the ... Read More

  • Pharmaceutical Wholesalers (EUROPEAN) - Industry Report

    ...PHARMA. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Wholesalers (EUROPEAN) analysis is ideal for anyone wanting to: • See the market leaders ... Read More

  • Pharmaceutical Wholesalers (GLOBAL) - Industry Report

    ...and KSK CO.,LTD.. This report includes a wealth of information on the financial trends over the past four years. Plimsoll Publishing’s latest Pharmaceutical Wholesalers (GLOBAL) analysis is ideal for anyone wanting to: • See the ... Read More

< prev 1 3 4 5 6 7 8 9 10